STSusan C. Taylor

Susan C. Taylor

*This is an algorithmically generated author record based on publicly available information.

Susan C. Taylor has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 April 2012
      • Vol. 11  (4) , 460-5

    Cultural competence and unique concerns in patients with ethnic skin.

    by Susan C Taylor, Candrice Heath

    The projections of increases in the number of skin of color patients over the next several decades, necessitates expertise in cultural competence for health care providers. Acquiring competency begins with practitioners reflecting on their self identity and personal beliefs. Additionally, understanding African-American cultural habits and practices and their impact on disease is critically important. We review, in this article, the fundamentals of becoming cultural competent. Patients are best served when their physician embraces their culture, their view of the health care system as well as habits and practices.


  • Safety of Nonanimal Stabilized Hyaluronic Acid Dermal Fillers in Patients with Skin of Color

    by Susan C. Taylor, Cheryl M. Burgess, Valerie D. Callender

    Nonanimal stabilized hyaluronic acid (NASHA) dermal fillers have been used in the United States since 2003 for the treatment of moderate to severe facial wrinkles and folds, such as nasolabial folds. Previous trials with NASHA dermal fillers have included small numbers of patients with pigmented skin. This randomized, evaluator-blinded, split-face trial compared the safety and efficacy of two variable-particle NASHA fillers in the correction of nasolabial folds in patients with Fitzpatrick skin types IV, V, and VI. One hundred fifty patients (predominantly African American) were enrolled at 10 sites. Patients received one treatment (with an optional touch-up treatment at week 2) with small- and large-particle NASHA gel randomized to the left or right side of the face. Safety was evaluated through patient diaries for the first 2 weeks and physician assessments at 3 days and 2, 6, 12, and 24 weeks after treatment for adverse events (AEs), skin pigmentation changes, and keloid formation. All related AEs were mild or moderate and of limited duration. They included bruising, tenderness, edema, redness, itching, pain, and changes in pigmentation. The incidence of AEs was not different between the 2 preparations, and no patient developed a keloid. There were 3 reported mass formations, 2 of which were infectious in nature. In patients with skin of color, NASHA dermal fillers are safe for the correction of moderate to severe facial folds and wrinkles, with no immunogenicity or keloid formation and only mild to moderate AEs occurring around the injection site.


    • 1 November 2005
      • Vol. 76  (5) , 302-6

    Enhancing the care and treatment of skin of color, part 2: understanding skin physiology.

    by Susan C Taylor

    Cutaneous diseases in patients with skin of color frequently present differently than in individuals with white skin. Increased understanding of skin physiology including skin lipids and barrier function, as well as documentation of common issues such as ashy skin, has been the focus of researchers. New insights into the effects of UV radiation in skin of color and the increasing incidence of malignant melanoma heighten awareness of the need for new initiatives directed at education and further research, despite previous views about photoprotection for this population.


    • 1 October 2005
      • Vol. 76  (4) , 249-55

    Enhancing the care and treatment of skin of color, part 1: The broad scope of pigmentary disorders.

    by Susan C Taylor

    Scientific research and technologies related to skin pigmentation and dyschromias, which are often key skin concerns for patients of color, have led to recent developments in skin care and treatment. Differences and similarities between skin of color and white skin and current issues in the treatment of ethnic skin are reviewed. Recent research findings, such as the elucidation of the protease-activated receptor 2 (PAR-2) pathway and its role in pigmentation, and areas for further investigation, such as the pathogenesis of pseudofolliculitis barbae (PFB), also are discussed. Awareness of this information within the wider community of dermatologists, primary healthcare providers, and the media will help to accomplish the objective of stimulating new prospective research.